Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$9,384,112

182 payments

Through program year 2025, Advanced Clinical Research LLC is reported as receiving $9,384,112 in research payments, across 182 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,986,544 51
2024 Research $1,443,599 69
2023 Research $759,194 13
2022 Research $888,724 16
2021 Research $1,017,120 16
2020 Research $611,157 11
2019 Research $677,773 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly Export S.A. Puerto Rico Branch $4,440,185 30 payments
  2. Eli Lilly and Company $2,896,590 50 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $870,166 10 payments
  4. Currax Pharmaceuticals LLC $758,942 18 payments
  5. Novartis Pharmaceuticals Corporation $238,468 8 payments
  6. Bausch Health US, LLC $120,415 56 payments
  7. Sanofi US Services Inc. $45,085 2 payments
  8. AbbVie, Inc. $10,154 3 payments
  9. GlaxoSmithKline, LLC. $4,108 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $1,564,249 4 payments
  2. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $776,918 10 payments
  3. NB (Contrave) Cardiovascular Outcomes Trial $758,942 18 payments
  4. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight and Type 2 Diabetes (Attain-2) $707,505 4 payments
  5. A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD $523,830 9 payments
  6. A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase 3 Study of Baricitinib in Patients With Covid 19 Infection $483,673 4 payments
  7. A Phase 3 Multicenter Randomized Parallel-Design Open-Label Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy $461,350 2 payments
  8. A Phase 2, Randomized, Parallel, Open-Label Comparator Controlled Trial to Evaluate the Safety and Efficacy of Ly3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy $350,566 4 payments
  9. Obesity Long term safety in patients with CV risk $346,336 1 payment
  10. A Study of Ly3209590 in Participants With Type 2 Diabetes Mellitus $317,025 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record